Staging preview: health content pending qualified review
D2C Peptides
CJC-1295 with DAC vial

CJC-1295 with DAC 2 mg

Also searched as: cjc 1295 dac, cjc-1295 dac, cjc 1295 with dac

Sold as CJC-1295 (DAC) - 2mg

$30 In stock

Strength
Ships from

For research use only. Not for human or veterinary use.

Ships from the USA or Canada. Shipping details

CJC-1295 with DAC is a synthetic analog of growth hormone-releasing hormone (GHRH).1 It joins a modified 29-amino-acid GRF(1-29) chain to an extra lysine that carries a maleimide group, the drug affinity complex (DAC), built to bind albumin in the blood.12 The vial holds 2 mg for laboratory research as freeze-dried (lyophilized) powder, the form FDA describes for CJC-1295 DAC.3 No form of CJC-1295 is part of an FDA-approved drug.4

Specifications

ClassGrowth hormone-releasing hormone (GHRH) analog; a maleimido derivative of hGRF(1-29)51
Sequence (one-letter code)YaDAIFTQSYRKVLAQLSARKLLQDILSRK-NH2 (a = D-alanine; the last K carries the DAC)5
Sequence (three-letter code)Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(MPA)-NH252
Molecular formulaC165H269N47O46 (DAC free base)5
Molar mass3647.2 g/mol5
CAS number446262-90-4 (PubChem marks 863288-34-0 as a deprecated number for this record)5
PubChem CID919718205
UNII62RC32V9N75
FormWhite freeze-dried (lyophilized) powder3
Water solubilityAbout 2 mg/mL (FDA, citing a supplier source)3
Salt formNot stated for this vial; FDA lists DAC free base, DAC acetate and DAC TFA forms41
Vial contents2 mg per vial
Strength2 mg
Ships fromUSA, Canada
CategoriesAnti-Aging Peptides, Growth Hormone Peptides, Healing and Recovery Peptides, Muscle Growth Peptides
StorageFDA's 2024 review, citing supplier sources, describes the powder as stored at -20 °C and expects it to be stable below -20 °C.63 Once dissolved, the peptide can be kept at 4 °C, divided into several vials to avoid repeated freezing and thawing.6

Supplies for CJC-1295 with DAC

Bulk and wholesale orders

Labs that need CJC-1295 with DAC in larger quantities can apply for a wholesale account. Terms are confirmed on application.

Wholesale detailsApply for a wholesale account

Questions about CJC-1295 with DAC

About CJC-1295 with DAC

CJC-1295 with DAC copies the active part of GHRH, the signal that tells the pituitary gland to release growth hormone (GH).10 Four of its 29 core amino acids are swapped, at positions 2, 8, 15 and 27, and an extra lysine at the end carries the DAC that binds the blood protein albumin.102 ConjuChem Biotechnologies of Montreal developed it and first described it in 2005.11

This page lists CJC-1295 with DAC for sale as a 2 mg research vial; the selector above shows the CJC-1295 with DAC price and stock for each shipping origin. The name CJC-1295 is also used for a peptide without the DAC; FDA treats it as a separate substance and says DAC results cannot be applied to it.112 Read What is CJC-1295 with DAC? for the full source review before you buy CJC-1295 with DAC for a study.

Research highlights

  • Rats (2005): an injection under the skin gave 4 times the GH exposure of unmodified hGRF(1-29) over 2 hours, and the peptide was still in plasma after 72 hours.2
  • Healthy adults (2006, two placebo-controlled trials of 42 and 24 people): one injection raised mean GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9 to 11 days, depending on dose. The estimated half-life was 5.8 to 8.1 days.132624
  • Healthy men (2006, 12 people): a week after one injection, baseline GH was 7.5 times higher, while the number and size of natural GH pulses did not change.1425
  • GHRH knockout mice (2006): daily dosing for 5 weeks gave normal body weight and length.15
  • Patients: the only patient trial, a phase 2 study in HIV-associated abdominal fat, was terminated after a participant died, and its data have not been published.1617
  • Animal safety (FDA review): repeated daily injections under the skin caused bleeding, inflammation and tissue death at the injection site in rats and dogs.18

Regulatory status

CJC-1295 is not FDA-approved, and no form of it has a USP or National Formulary monograph.4 On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 0 to 13 against adding CJC-1295 DAC free base to the 503A bulks list, the list of substances pharmacies may compound with.19 FDA lists CJC-1295 among bulk substances that may present significant safety risks, citing possible immune reactions, problems with peptide impurities and characterization, and serious adverse events including increased heart rate and systemic vasodilatory reactions.20 The 2026 WADA Prohibited List bans it in sport at all times, under class S2.2.4.21 In Canada, a Health Canada advisory of April 9, 2026 names CJC-1295 among seized unauthorized injectable peptides and says research-use labelling does not make such products legal.22

Handling and storage

FDA warns that peptides like CJC-1295 can clump and break down when pH, heat or concentration changes, and that clumped (aggregated) peptide also raises the risk of immune reactions.723 FDA, citing a supplier source, reports a water solubility of about 2 mg/mL, so 2 mg of powder needs roughly 1 mL of liquid or more to dissolve.3 Lab steps and concentration math are in How to reconstitute CJC-1295 with DAC; the reconstitution calculator does the arithmetic for any diluent volume.

Frequently asked questions

Where does CJC-1295 with DAC ship from?

Orders ship from the USA and Canada to addresses across the United States. When a vial is listed with more than one shipping origin, the selector above lets you pick one and shows its stock before checkout. Delivery options and times are listed on the shipping page, so check it before you order.

How should CJC-1295 with DAC be stored when it arrives?

No approved label gives official storage instructions.4 FDA's 2024 review, citing supplier sources, describes the powder as stored at -20 °C (freezer), where FDA expects it to be stable, and the dissolved peptide as kept at 4 °C (refrigerator) in several small vials to avoid repeated freezing and thawing.63

What strengths of CJC-1295 with DAC are available?

Strengths listed: 2 mg, each a single vial of freeze-dried powder. CJC-1295 without DAC, which FDA treats as a separate active substance, has its own page as CJC-1295 No DAC,1 and a CJC-1295 + Ipamorelin blend is listed too, so check the name on the label.

Is there a certificate of analysis for CJC-1295 with DAC?

See the lab results page for available testing documents. For this compound, look for an identity result as well as purity: FDA calls inconsistent naming of CJC-1295 substances a safety risk,1 and a molecular mass result tells the DAC form (3647.2 g/mol) from the form without DAC (3367.95 g/mol).57

What supplies are used with a CJC-1295 with DAC vial?

The vial holds dry powder, so a lab dissolves it in a diluent such as bacteriostatic water, measures the solution with insulin syringes and wipes vial stoppers with alcohol swabs. Volumes and steps are in How to reconstitute CJC-1295 with DAC. These are lab handling steps, not directions for use in people.

Is CJC-1295 with DAC for human use?

No. It is sold for laboratory research, and every vial is labeled: For research use only. Not for human or veterinary use. No form of CJC-1295 is part of an FDA-approved drug,4 and FDA found no studies in which any form was given to people with a disease or condition.8 The human studies that exist gave it to small groups of healthy adults for short periods.9

Written by D2C Peptides Editorial Team.

Pending qualified review.

Updated .

Sources

  1. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 10, naming and identity). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  2. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog (Jette L et al., ConjuChem), PubMed PMID 15817669. Endocrinology (abstract via NCBI PubMed E-utilities), 2005.
  3. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 19, CJC-1295 DAC properties and conclusions). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  4. FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of December 4, 2024: FDA Evaluation of CJC-1295-related bulk drug substances (PDF page 7, Introduction). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  5. PubChem compound record CID 91971820 (Cjc 1295). PubChem, National Library of Medicine (NIH), 2026.
  6. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 17, CJC-1295 DAC stability). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  7. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 12, CJC-1295 free base chemistry and peptide stability). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  8. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 24, compounding history and human use). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  9. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 54, conclusion and recommendation). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  10. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 29, general pharmacology). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  11. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 23, history of use and development). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  12. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 31, DAC caveats and pharmacokinetics). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  13. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (Teichman SL et al.), PubMed PMID 16352683. Journal of Clinical Endocrinology and Metabolism (abstract via NCBI PubMed E-utilities), 2006.
  14. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog (Ionescu M, Frohman LA), PubMed PMID 17018654. Journal of Clinical Endocrinology and Metabolism (abstract via NCBI PubMed E-utilities), 2006.
  15. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse (Alba M et al.), PubMed PMID 16822960. American Journal of Physiology, Endocrinology and Metabolism (abstract via NCBI PubMed E-utilities), 2006.
  16. NCT00267527: A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity (ConjuChem), ClinicalTrials.gov record. ClinicalTrials.gov, U.S. National Library of Medicine, 2006.
  17. Transcript, FDA Pharmacy Compounding Advisory Committee meeting, December 4, 2024, CJC-1295 topic (FDA presentation, page 84). U.S. Food and Drug Administration, 2024.
  18. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 36, nonclinical toxicology conclusions). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  19. Transcript, FDA Pharmacy Compounding Advisory Committee meeting, December 4, 2024, CJC-1295 topic (Question 1D vote on CJC-1295 DAC free base, pages 130 to 131; separate votes on the other forms follow). U.S. Food and Drug Administration, 2024.
  20. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). U.S. Food and Drug Administration, 2026.
  21. Tractatenblad 2026, 25: Anti-Doping Convention (ETS No. 135), amendment to the appendix: The 2026 Prohibited List, World Anti-Doping Code. Kingdom of the Netherlands, Ministry of Foreign Affairs (official publication of the WADA 2026 Prohibited List), 2026.
  22. Think twice before injecting peptides bought online: unauthorized products can seriously harm you (public advisory RA-81874, April 9, 2026). Health Canada, Government of Canada, 2026.
  23. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 43, immunogenicity). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  24. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 38, Teichman 2006 study details). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  25. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 39, Ionescu and Frohman 2006 details). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
  26. FDA Briefing Document, PCAC December 4, 2024, CJC-1295 evaluation (PDF page 40, adverse event reports and phase 2 trial). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2024.
Shop all peptidesMore anti-aging peptides